STOK Stoke Therapeutics
- 14.130
- +1.330+10.39%
- 14.200
- +0.070+0.50%
Stoke Therapeutics News
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Stoke Therapeutics Analyst Ratings
Buy Rating for Stoke Therapeutics With Adjusted Price Target Amid Regulatory and Developmental Progress
Stoke Therapeutics Analyst Ratings
Buy Rating Justified by Stoke Therapeutics' Promising Pipeline and Strategic Market Positioning
Stoke Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics' STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial Outlook
Wedbush Sticks to Their Buy Rating for Stoke Therapeutics (STOK)
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Elevance Health (ELV) and Stoke Therapeutics (STOK)
Stoke Therapeutics' STK-001 Shows Promising Results: A Strong Buy Rating With Increased Price Target
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics Analyst Ratings
Buy Rating for Stoke Therapeutics: Anticipating STK-001's Breakthrough in Dravet Syndrome Treatment
Buy Rating Affirmed for Stoke Therapeutics Amid Promising Drug Developments and Market Potential
Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Alpha Teknova (TKNO)
Optimistic Buy Rating for Stoke Therapeutics on STK-001's Potential in Dravet Syndrome and Promising STK-002 ADOA Treatment Pipeline
Analysis
Price Target
No Data
